Circulation-Heart Failure

Article	Citations
Cognitive and Procedural Competencies in the Cardiac Intensive Care Unit	138
High-Dose vs. Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial	105
Equity in Heart Failure Care: A Get With the Guidelines Analysis of Between- and Within-Hospital Differences in Care by Sex, Race, Ethnicity, and Insurance	98
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy	98
Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure	93
Early Outcomes in Patients With LVAD Undergoing Heart Transplant via Use of the SherpaPak Cardiac Transport System	92
Characteristics of United States Counties in Which Heart Failure Clinical Trials of Pharmacotherapy Were Conducted	76
Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure	70
Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group	70
GDMT Optimization, But Make It Patient-Centered: Understanding Patient Needs During Heart Failure Medication Discussions	68
Identifying Discordance of Right- and Left-Ventricular Filling Pressures in Patients With Heart Failure by the Clinical Examination	64
Letter by Qiu and Du Regarding Article, “Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”	55
Infarct Size Reduction With Cyclosporine A in Circulatory Death Rat Hearts: Reducing Effective Ischemia Time With Therapy During Reperfusion	52
Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial	50
Epicardial Fat Paradox and Differential Effects of GLP-1 Receptor Agonists Across Heart Failure Phenotypes	50
Association of Pulmonary Artery Pulsatility Index With Adverse Cardiovascular Events Across a Hospital-Based Sample	49
Longitudinal Trends in Donor and Recipient Risk Profile, and Clinical Outcomes, for Donation After Circulatory Death Heart Transplantation	48
National Organ Procurement and Transplant Network Heart Allocation Policy: 6 Years Later	45
Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy	44
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program	42
Impact of Multimorbidity on Mortality in Heart Failure With Mildly Reduced and Preserved Ejection Fraction	41
Failing to Make the Grade: Conventional Cardiac Allograft Rejection Grading Criteria Are Inadequate for Predicting Rejection Severity	40
Health-Related Quality of Life in Older Patients With Heart Failure From Before to Early After Advanced Surgical Therapies: Findings From the SUSTAIN-IT Study	40
Prolonged Extreme Asymptomatic Hypertroponinemia as a Milestone in Diagnosis of Familial Arrhythmogenic Right Ventricular Cardiomyopathy	39
Trajectory of Cognitive Function After Incident Heart Failure	39

Ongoing Enigma of NT-proBNP in HFpEF: Insights From Proteomics	39
Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death	37
Pseudo-Severe Mitral Stenosis From Obesity-Related HFpEF and Atrial Myopathy	36
Diastolic Perfusion Pressure Predicts Response to Inotropes and Vasopressors and Benefit From Mechanical Circulatory Support in Cardiogenic Shock	35
Letter by Baldovino et al Regarding Article, “Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy”	34
Long-Term Functional Outcomes in the First 12 Months After VA-ECMO in Adult Patients: A Prospective, Multicenter Study	34
Increased Chamber Resting Tone Is a Key Determinant of Left Ventricular Diastolic Dysfunction	33
Predicting 1-Year Mortality in Outpatients With Heart Failure With Reduced Left Ventricular Ejection Fraction: Do Empiric Models Outperform Physician Intuitive Estimates? A Multicenter Cohort Study	33
Rethinking the Nomenclature of Heart Failure Cardiogenic Shock: Do We Need to Start De Novo?	32
Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications	32
Rethinking Donor and Recipient Risk Matching in Europe and North America: Using Heart Transplant Predictors of Donor and Recipient Risk	31
Incidence and Outcomes of Advanced Heart Failure in Adults With Congenital Heart Disease	31
Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review	31
Current Approach to the Diagnosis of Sarcopenia in Heart Failure: A Narrative Review on the Role of Clinical and Imaging Assessments	30
Predicted Heart Mass: A Tale of 2 Ventricles	30
Knowing All the Angles (on Right Ventricular Myocardial Remodeling)	29
Hierarchical Analysis of Composite Time-to-Event End Points in Heart Failure Clinical Trials Using Time in Clinical State	29
Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury	29
Pressure Overload–Induced Cardiac Hypertrophy Stimulates Tumor Growth in Tumor-Prone Apc Min Mice	29
Correction to: “Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure”	28
Letter by Inker et al Regarding Article, “Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical	28
Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis	28
Easing the Strain: Atrial Function After Atrial Shunting	27
Peripheral Venous Pressure+Fenestration Doppler=Noninvasive Cardiac Catheterization Post-Fontan	27
Letter by Hu Regarding Article, “Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death”	27
Use of a Cardiac Scale to Predict Heart Failure Events: Design of SCALE-HF 1	27
Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure	27
Response by Prisco and Prins to Letter Regarding Article, “Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Junctophilin-2 to Altered Mitochondrial Metabolism and Right Ventri	27
Proving SGLT2 Inhibitor-Mediated Improvement in Cardiomyocyte Energetics: Beyond a Reasonable Doubt?	27
When the Whole Is the Sum of Its Parts: Validation of the Heart Failure Collaboratory Medication Composite Score in Denmark	26
Home-Time, Mortality, and Readmissions Among Patients Hospitalized With Heart Failure: A Baseline Prior to IMPLEMENT-HF	26
Will the SGLT2i Responders Please Stand Up?	26
Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction	26
Single Arterial Access for VA-ECMO–Assisted Stenting of a Left Ventricular Assist Device Outflow Graft Obstruction in the Setting of an Oversewn Aortic Valve	26
Letter by Lim Regarding Article, “The Pitfalls in the World of Evidence-Based Medicine: Should IABP Be en-DANGER-ed by the Danger Shock Trial?”	25
Cardiomyopathy Across the Tree of Life: Insights for Clinicians and Investigators	25
Sympathetic Response to 1-Leg Cycling Exercise Predicts Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction	25
PHM in Heart Transplantation: From Predicted Heart Mass to Practical Heart Matching	25
Response by Brahmbhatt et al to Letter Regarding Article, “Liberation From Venoarterial Extracorporeal Membrane Oxygenation: A Review”	24
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial	24
Race, Social Determinants of Health, and Length of Stay Among Hospitalized Patients With Heart Failure: An Analysis From the Get With The Guidelines-Heart Failure Registry	24
Letter by Kounis et al Regarding Article, “Biopsy-Proven Giant Cell Myocarditis Following the COVID-19 Vaccine”	24
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF	24
Mucopolysaccharidosis Type IIIA Presenting as Hypertrophic Cardiomyopathy	23
Targeting Preload in Heart Failure: Splanchnic Nerve Blockade and Beyond	23
Socioeconomic Disparities Are Associated With Delayed Access to Tafamidis in Transthyretin Cardiac Amyloidosis	23
Race, Sex, and Age Disparities in the Performance of ECG Deep Learning Models Predicting Heart Failure	23
Mosaic Loss of the Y Chromosome Is Enriched in Patients With Wild-Type Transthyretin Cardiac Amyloidosis and Associated With Increased Mortality	23
Uncovering Unrecognized Heart Failure With Preserved Ejection Fraction Among Individuals With Obesity and Dyspnea	22
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF	22

Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure	22
Markets, Messaging, and Mastery: Reframing the Conversation Around the Heart Failure Physician Workforce	22
Unraveling the Pathophysiological Mechanisms of Phospholamban R14del Cardiomyopathy: A Comprehensive Overview	22
Impact of the Swedish Care Coordination Act on Heart Failure Readmissions and Length of Stay	22
Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study	22
Ironing Out the Controversies Surrounding the Iron Deficiency Definition in Heart Failure	22
A Sweet Solution for Heart Failure With Preserved Ejection Fraction: The Role of Sodium-Glucose Cotransporter-2 Inhibitors	21
Social Determinants of Health and Heart Failure: Clinical Takeaways From 5 Pivotal Analyses of the GWTG-HF Registry	21
First Bicaval Valve Implantation in a Heart Transplant Patient to Treat Severe Symptomatic Tricuspid Regurgitation	21
Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin	20
Skeletal Muscle Mass Recovery Early After Left Ventricular Assist Device Implantation in Patients With Advanced Systolic Heart Failure	20
Antecedent Flu-Like Illness and Onset of Idiopathic Dilated Cardiomyopathy: The DCM Precision Medicine Study	20
Transfer to Hub Hospitals and Outcomes in Cardiogenic Shock	20
Novel Small-Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics	19
Pulsus Alternans in Cardiogenic Shock Recapitulated in Single Cell Fluorescence Imaging of a Patient’s Cardiomyocyte	19
Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart Failure	19
Response by Schlender et al to Letter Regarding Article, “Disseminated Intracardiac Thrombosis Due to Long-Standing, Asymptomatic Ventricular Fibrillation Under Left Ventricular Assist Device Support”	19
Plasma Proteome Analysis Identifies Vascular Endothelial Growth Factor Receptor 1 as a Prognostic Biomarker in Cardiogenic Shock	19
Harnessing the Plasma Proteome to Predict Mortality in Heart Failure Subpopulations	19
Defining the Specific Skeletal Muscle Adaptations Responsible for Exercise Training Improvements in Heart Failure With Preserved Ejection Fraction	18
SGLT2 Inhibitor–Related Polycythemia in a Patient With Chronic Heart Failure: A Potential Severe Adverse Event	18
Patient Perceptions and Knowledge Surrounding Pregnancy After Heart Transplantation: A Multicenter Study	17
Cardiorenal Syndrome: An Evolutionary Appraisal	17
Comparison of Blood Volume Profiles in Heart Failure With Preserved and Reduced Ejection Fractions: Sex Makes a Difference	17
NETosis Is an Important Component of Chronic Myocardial Inflammation in Patients With Heart Failure	17
Pulmonary Artery Pressure-Guided Heart Failure Management Reduces Hospitalizations in Patients With Chronic Kidney Disease	17
Sex Differences in Skeletal Muscle Pathology in Patients With Heart Failure and Reduced Ejection Fraction	17
Sex-Associated Differences in the Clinical Outcomes of Left Ventricular Assist Device Recipients: Insights From Interagency Registry for Mechanically Assisted Circulatory Support	16
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update	16
SGLT2 Inhibitors and Their Effect on Metabolism in Patients With Heart Failure	16
Clinical Prediction Model for Antibody-Mediated Rejection: A Strategy to Minimize Surveillance Endomyocardial Biopsies After Heart Transplantation	16
Racial and Social Vulnerability Hotspots in Premature Heart Failure Mortality Across US Counties	16
Quantification of Vasoactive Medications and the “Pharmaco-Mechanical Continuum” in Cardiogenic Shock	16
Succinylation of SERCA2a at K352 Promotes Its Ubiquitinoylation and Degradation by Proteasomes in Sepsis-Induced Heart Dysfunction	16
Are Men and Women That Different?	15
Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial	15
Unexplained Dyspnea on Exertion: The Difference the Right Test Can Make	15
Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial	15
Acute Pulmonary Edema During Impella RP Support: Too Much of a Good Thing	15
Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF	15
Improving Fairness in the Prediction of Heart Failure Length of Stay and Mortality by Integrating Social Determinants of Health	15
Case Implementing 2022 AHA/ACC/HFSA Guidelines: Heart Failure Management in Pregnancy: Early Planning, Close Surveillance, and Multidisciplinary Care	15
Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization	15
Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy	15
Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial	14
Trending Cardiac Biomarkers During Pregnancy in Women With Cardiovascular Disease	14
Nitric Oxide–Mediated Coronary Endothelial Function Is Impaired in Patients With Heart Failure With Preserved Ejection Fraction	14
Simultaneous or Rapid Sequence Optimization of Medical Therapy for Heart Failure: Time to Keep Score	14
Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies	14
Outcomes of Combined Heart and Kidney Transplantation Under the New Heart Allocation Policy: A United Organ Network for Organ Sharing Database Analysis	14
Integrative Multiomics for Prognostic Assessment in Pulmonary Arterial Hypertension	14
Modulation of Pulsatile Left Ventricular Afterload by Renal Denervation in Heart Failure With Preserved Ejection Fraction	14
Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity	14
Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction	14
Early Outcomes of Heart Transplantation Using Donation After Circulatory Death Donors in the United States	13
Treatment With Myosin Inhibitor in a Patient With Symptomatic Hypertrophic Cardiomyopathy With Isolated Right Ventricular Obstruction	13
Conceptualizing Liberation From Venoarterial Extracorporeal Membrane Oxygenation	13
You Are Where You Eat: The Local Environment and Risk of Heart Failure	13
Ubiquity of Multimorbidity: Comorbid Conditions and Mortality in HFpEF	13
Neurohormonal and Renal Effects of 14-Day Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction	13
Precision Medicine Is in the Eye of the Beholder	13
Response by Park et al to Letter Regarding Article, “Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to	13
Edge-to-Edge Transcatheter Mitral Valve Repair Versus Optimal Medical Treatment in Nonresponders to Cardiac Resynchronization Therapy: The MITRA-CRT Trial	13
Letter by Shah Regarding Article, “Reversible Cause of Heart Failure?”	13
Late-Life Echocardiographic Effects of the Amyloidogenic p.V142I Transthyretin Variant	13
Letter by ten Berg et al Regarding Article, “Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Regis	13
Risk of Worsening Heart Failure and All-Cause Mortality Following COVID-19 Vaccination in Patients With Heart Failure: A Nationwide Real-World Safety Study	12
Abnormal Left Atrial Strain by CMR Is Associated With Left Heart Disease in Patients With Pulmonary Hypertension	12
Impact of Heart Transplant Allocation Change on Waitlist Mortality and Posttransplant Mortality in Patients With Left Ventricular Assist Devices	12
Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry	12
Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves	12
Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction	12
Combined Loss of Obsc and Obsl1 in Murine Hearts Results in Diastolic Dysfunction, Altered Metabolism, and Deregulated Mitophagy	12
Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease	12
Use of a Pulmonary Artery Pressure Sensor to Manage Patients With Left Ventricular Assist Devices	12
Response by Glargaard et al to Letter Regarding Article, “Pleural Effusion and Invasive Hemodynamic Measurements in Advanced Heart Failure”	11
Changes in Heart Transplant Listings by Insurance and Race During the COVID Public Health Emergency	11
Iron Deficiency Induces Heart Failure With Ectopic Cardiac Calcification in Mice With Metabolic Syndrome	11
Disseminated Intracardiac Thrombosis Due to Long-Standing, Asymptomatic Ventricular Fibrillation Under Left Ventricular Assist Device Support	11
Pathological Analysis of T1 Pseudonormalization in the Advanced Stage of Female Fabry Cardiomyopathy	11

Continuous-Flow Intra-Aortic Percutaneous Mechanical Circulatory Support in Heart Failure With Worsening Renal Function	11
Myocardial DNA Damage Is Responsible for the Relationship Between Genotype and Reverse Remodeling in Patients With Dilated Cardiomyopathy	11
Response by Jentzer et al to Letters Regarding Article, “Exposure to Arterial Hyperoxia During Extracorporeal Membrane Oxygenator Support and Mortality in Patients With Cardiogenic Shock”	11
Response by Reddy to Letter Regarding Article, “Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death”	11
Acute Heart Failure Caused by Rupture of Sinus of Valsalva Into Right Atrium in a Patient With Possible Infective Endocarditis After Tricuspid Annuloplasty: A Misdirected Clinical Decision-Making	11
Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study	11
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial	10
Significance of Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients With Negative Endomyocardial Biopsies: A Dawn of a New Era	10
Transfusions in Heart Failure and Acute Myocardial Infarction: Novel Data Begets New Questions	10
Right Ventricular Function, Inflammation, and the Gut Microbiome in Pulmonary Hypertension: A Translational Frontier	10
Correction to: Response to Letter Regarding Article “Characterizing Gender Differences in Physical Frailty Phenotypes in Heart Failure”	10
Combining Minimally Invasive Surgery With Ultra-Fast-Track Anesthesia in HeartMate 3 Patients: A Pilot Study	10
Patients Who Donate Biospecimens for Research Leave a Valuable and Underappreciated Scientific Legacy	10
Musclin and HFpEF: Unlocking Skeletal Muscle Potential to Improve Exercise Tolerance	10
Long-Term Trajectories of Left Heart Geometry, Mechanics, and Oxygen Demand After Bariatric Surgery	10